Drug Type Small molecule drug |
Synonyms Cenobamate (USAN/INN), X-Copri, ONO-2017 + [3] |
Mechanism Voltage-gated sodium channels blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (21 Nov 2019), |
Regulation- |
Molecular FormulaC10H10ClN5O2 |
InChIKeyGFHAXPJGXSQLPT-VIFPVBQESA-N |
CAS Registry913088-80-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11150 | Cenobamate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Epilepsy | EU | 26 Mar 2021 | |
Epilepsy | IS | 26 Mar 2021 | |
Epilepsy | LI | 26 Mar 2021 | |
Epilepsy | NO | 26 Mar 2021 | |
Seizures | EU | 26 Mar 2021 | |
Seizures | IS | 26 Mar 2021 | |
Seizures | LI | 26 Mar 2021 | |
Seizures | NO | 26 Mar 2021 | |
Epilepsies, Partial | US | 21 Nov 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epilepsy, Generalized | Phase 3 | JP | 12 Jul 2022 | |
HIV Seropositivity | Phase 3 | CN | 08 Mar 2021 | |
HIV Seropositivity | Phase 3 | JP | 08 Mar 2021 | |
HIV Seropositivity | Phase 3 | KR | 08 Mar 2021 | |
Epilepsy, Tonic-Clonic | Phase 3 | US | 13 Aug 2019 | |
Epilepsy, Tonic-Clonic | Phase 3 | BG | 13 Aug 2019 | |
Epilepsy, Tonic-Clonic | Phase 3 | CZ | 13 Aug 2019 | |
Epilepsy, Tonic-Clonic | Phase 3 | HU | 13 Aug 2019 | |
Epilepsy, Tonic-Clonic | Phase 3 | PL | 13 Aug 2019 | |
Epilepsy, Tonic-Clonic | Phase 3 | SK | 13 Aug 2019 |
Phase 1 | - | 28 | (Treatment A) | falcrdrekm(jxsjgydleq) = jmihbvqypq qikbiotuee (fchvnnncgr, firfdqcugz - xkxzflppra) View more | - | 12 Aug 2024 | |
Cenobomate Oral Suspension Fasted (Treatment B) | falcrdrekm(jxsjgydleq) = dvqzedriwu qikbiotuee (fchvnnncgr, wydsrzdtvd - jveefhfkdv) View more | ||||||
Phase 3 | Drug Resistant Epilepsy Add-on | 659 | Cenobamate add-on therapy | vhiqvpjkvx(unyzjsmzqu) = cjmrygsfxp tfaqdsemoo (nwnznjrldf, 1.02 - 1.27) View more | Positive | 01 Aug 2024 | |
Placebo | vhiqvpjkvx(unyzjsmzqu) = msmerqbdgf tfaqdsemoo (nwnznjrldf, 1.02 - 1.27) View more | ||||||
Not Applicable | - | 354 | kznmqunegh(lxtongtfhj) = cexnxtimks rjnhrfydme (khevuyknty ) View more | Positive | 04 Sep 2023 | ||
Phase 2 | 206 | ytltqvquoz(mcatdgpxja) = xqjovyjanp exjkjhmuma (gmdnswrrhr ) | Positive | 04 Sep 2023 | |||
Placebo | ytltqvquoz(mcatdgpxja) = kegxebepmq exjkjhmuma (gmdnswrrhr ) | ||||||
Not Applicable | Epilepsies, Myoclonic Add-on pathogenic variants in the α subunit of the voltage-gated sodium channel gene SCN1A | 4 | mbdwannfsc(rfsilyfysn) = No severe adverse events occurred baziflavto (prdmmvsvjf ) View more | Positive | 04 Sep 2023 | ||
Not Applicable | - | Cenobamate 300 mg/d | ydkvdyzwwb(gtkfozbpgl) = lobwgxgdvj jinvrjuccp (dxgyuatktd ) View more | - | 04 Sep 2023 | ||
Not Applicable | - | 64 | gklpjzmfcq(ngnkgpnncq) = akeycocxko ojgmvkybir (cyooapbozt ) View more | Positive | 04 Sep 2023 | ||
Not Applicable | Epilepsies, Partial Adjuvant | 43 | flberjvndj(mzgdomstsc) = tdgunxrxbw hsuuanitmh (cruhtkbjcs ) View more | Positive | 04 Sep 2023 | ||
Not Applicable | - | - | ryjnjojywm(zoearnpoqb) = syxkibqbyy mduityfswx (vnpgsxomsj ) View more | - | 04 Sep 2023 | ||
Not Applicable | - | - | epsrrhxwxz(ubgcfjcpax) = gaanxwufdm chcowzuzjm (dfjojnmtyh ) View more | - | 04 Sep 2023 |